8-K filed Nov 2, 2026 at 21:58 ET
Karyopharm Therapeutics filed a prepackaged Chapter 11 bankruptcy on November 2, 2026, supported by 100% of its secured creditors. The plan provides for a reorganization transaction merging the company with Ayrmid Ltd., where secured funded debt claims (~$276M) will be exchanged for 55% of NewCo common stock and contingent value rights tied to myelofibrosis sales. Existing common and preferred equity will be canceled with no recovery. A court-supervised sale process continues with a $335.4M minimum bid threshold. The company had $8.1M cash at filing against ~$390M in total funded debt obligations.